Skip to content
Screener

LivaNova LIVN Neuromodulation — R&D

Other segment segments

Cardiopulmonary
$18.38M+11.6%

Similar metrics at other companies

Insmed logo
INSMARIKAYCE external R&D expenses — R&D
$6.23M-43.4%
Insmed logo
INSMBrensocatib external R&D expenses — R&D
$13.83M-58.8%
Insmed logo
INSMTPIP external R&D expenses — R&D
$38.94M+88.6%
Insmed logo
INSMOther external R&D expenses — R&D
$48.84M+71.7%
Micron Technology logo
MUAEBU — R&D
$109M+0.9%
Micron Technology logo
MUCDBU — R&D
$358M+76.4%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemCardiopulmonary / Three Months Ended June 30, 2026Cardiopulmonary / Three Months Ended June 30, 2025Neuromodulation / Three Months Ended June 30, 2026Neuromodulation / Three Months Ended June 30, 2025
Less:
Cost of sales97,26595,46514,45514,769
Selling, general, and administrative66,46556,01256,56851,097
Research and development18,37616,46534,98729,784
3T litigation provision11,318(77)——
$28,152$31,407$60,935$56,020
CardiopulmonaryNeuromodulation
Six Months Ended June 30,Six Months Ended June 30,

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's neuromodulation — R&D?
LivaNova (LIVN) reported neuromodulation — R&D of $34.99M in Q2 2026.
How has LivaNova's neuromodulation — R&D changed year-over-year?
LivaNova's neuromodulation — R&D increased by 17.5% year-over-year, from $29.78M to $34.99M.
What is the long-term trend for LivaNova's neuromodulation — R&D?
Over 3 years (2022 to 2025), LivaNova's neuromodulation — R&D has grown at a 1.5% compound annual growth rate (CAGR), from $113.62M to $118.92M.
What does neuromodulation — R&D mean?
Represents expenditures dedicated to the innovation, clinical trials, and development of new neuromodulation technologies and product enhancements. This is a critical indicator of the segment's long-term competitive positioning and future growth pipeline.

Ask your AI about LivaNova's neuromodulation — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude